Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07502443 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
A Phase 3 study, sponsored by Alkermes.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 176
- Enrollment target
NCT07502443 is a Phase 3 study that is actively recruiting participants, run by Alkermes. The registered enrollment target is 176 participants.
The verdict
NCT07502443, a Phase 3 study, is actively recruiting participants, sponsored by Alkermes.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 176 participants
- Enrollment target
Study Summary
The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.
Interventions
- DRUG Placebo
- DRUG ALKS 2680 Dose 1
- DRUG ALKS 2680 Dose 2
- DRUG ALKS 2680 Dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2026-04-22 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07502443
The ClinicalTrials.gov registry entry for NCT07502443 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07502443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07502443 about?
NCT07502443 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2". The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.
What is the current status of trial NCT07502443?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 176 participants. The study started on 2026-04-22. Estimated completion is 2027-06.
What interventions are being tested in trial NCT07502443?
The interventions under investigation include: Placebo (DRUG), ALKS 2680 Dose 1 (DRUG), ALKS 2680 Dose 2 (DRUG), ALKS 2680 Dose 3 (DRUG).
Who is sponsoring clinical trial NCT07502443?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.